ITCI:NSD-Intracellular Th (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 88.22

Change

-0.27 (-0.31)%

Market Cap

USD 9.17B

Volume

0.98M

Analyst Target

USD 45.25
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-13 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
VTRS Viatris Inc

+0.07 (+0.54%)

USD 13.87B
NBIX Neurocrine Biosciences Inc

-1.50 (-1.18%)

USD 12.37B
LNTH Lantheus Holdings Inc

-5.39 (-6.33%)

USD 7.63B
ALKS Alkermes Plc

+0.01 (+0.03%)

USD 4.73B
ALVO Alvotech

-0.23 (-1.89%)

USD 3.67B
HCM HUTCHMED DRC

-0.44 (-2.52%)

USD 3.18B
AMPH Amphastar P

-2.23 (-4.67%)

USD 2.29B
SUPN Supernus Pharmaceuticals Inc

-0.06 (-0.16%)

USD 1.93B
HROW Harrow Health Inc

+1.89 (+3.79%)

USD 1.86B
KNSA Kiniksa Pharmaceuticals Ltd

-0.37 (-1.61%)

USD 1.59B

ETFs Containing ITCI

PSIL AdvisorShares Psychedelic.. 4.46 % 0.00 %

-0.24 (-1.26%)

USD 6.37M
IBRN iShares Trust - iShares N.. 4.16 % 0.00 %

-0.35 (-1.26%)

USD 4.01M
FBT:LSE First Trust Global Funds .. 3.79 % 0.00 %

+5.20 (+-1.26%)

USD 8.45M
FBTU:LSE First Trust Global Funds .. 3.79 % 0.00 %

-0.06 (-1.26%)

USD 8.45M

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 23.18% 79% B- 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 23.18% 76% C+ 75% C
Trailing 12 Months  
Capital Gain 55.62% 82% B 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 55.62% 82% B 83% B
Trailing 5 Years  
Capital Gain 878.05% 100% F 99% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 878.05% 100% F 99% N/A
Average Annual (5 Year Horizon)  
Capital Gain 40.44% 76% C+ 85% B
Dividend Return 40.44% 76% C+ 84% B
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 36.31% 71% C- 52% F
Risk Adjusted Return 111.39% 100% F 98% N/A
Market Capitalization 9.17B 97% N/A 92% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.